StemCell Therapy

Exercise may reduce, and even reverse, bone loss caused by acidic hormone and radiation therapies used in the treatment of localized prostate cancer, thereby decreasing the potential risk of bone fractures and improving quality of life for these men, according to a study presented on October 28, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

"Prostate cancer patients are not routinely advised to exercise. Walking is one tool that prostate cancer patients can use to improve their health and minimize the side effects of cancer and cancer treatments," said Paula Chiplis, PhD., RN, the lead author of the study and a clinical instructor and senior research assistant at Johns Hopkins Hospital in Baltimore.

"Walking has no harmful side effects, if done moderately, but it can dramatically improve life for men suffering from side effects from some prostate cancer treatments."

Men with localized prostate cancer frequently receive radiation therapy followed by months of acidic hormone therapy to treat their cancerous acidic state. Read more...

Cardiofy Heart Care Supplement

BOSTON--A novel treatment for HIV could involve changing the genes in a person's immune cells and, ultimately, in his or her stem cells, as well. It might even lead to a cure for that deadly disease. Promising advances in that direction were presented here Monday at the 18th Conference on Retroviruses and Opportunistic Infections.

The pieces have been coming together for some time. First came the understanding that HIV enters a cell by grabbing on to a CD4 receptor molecule on the surface, and then on to a co-receptor molecule--the one most commonly used is called CCR5.

[More]

Original Article Source - Mass High Tech

Advanced Cell Technology Inc. has been given a patent for its nondestructive technique of obtaining human embryonic stem cell (hESC) lines. Called “single-blastomere” technology, the technique was referred to in a statement by ACT interim chairman and CEO Gary Rabin as “one of the most significant” among the Marlborough biotech’s more than 150 patents and patent applications.

“It will help us accelerate our progress on a number of fronts, including deriving embryonic stem cells which meet the regulatory standards of the European Medicines Agency and the US Food and Drug Administration, using the single-blastomere technology,” Rabin said, in the statement.

ACT (OTCBB: ACTC) said in a news release that its single-blastomere technique avoids embryo destruction by using a one-cell biopsy approach.

In January, the company pulled in a $25 million financing and was cleared by the FDA for its Investigational New Drug application to use hESCs in treating Dry Age-Related Macular Degeneration.

Rabin has been serving in his interim roles at ACT since mid-December, when William M. Caldwell IV, then chairman and CEO, died unexpectedly. Caldwell had held the CEO role of ACT since 2005 and the chairman post since 2006.

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its wholly owned subsidiary Lifeline Skin Care, Inc. ("LSC"), has now completed its evaluation of the highly successful trial launch of its new stem cell skin care product line in November and December 2010, and will move forward with its general marketing program.

Lifeline Skin Care products contain parthenogenetic stem cell extract and were developed by the ISCO research team in collaboration with world recognized cosmetic chemists. The breakthrough products deliver leading advances in skin rejuvenation technology that help to prevent and repair damaged skin. The products are available through our online store at http://www.lifelineskincare.com.

"Sales to date have greatly exceeded our expectations for the trial launch. These initial sales resulted from a very limited product offering made to subscribers of only one of the several newsletters of our marketing partner, John Mauldin, plus a small direct mailing to interested parties and ISCO's shareholders who had signed up for general corporate information through the ISCO website," said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.

Lifeline Skin Care is now ready to move forward to the next phase of distribution, which will commence near the end of March. That phase will consist initially of a customer solicitation conducted by John Mauldin's specialty Internet and direct response marketing organization. "We almost never endorse or sell a retail product," said Mr. Mauldin, "but the results of both our informal testing and the company's formal studies have convinced us that the Lifeline Skin Care products really are a game-changing advance in skin care. I have not seen such a strong response in online marketing in the last ten years. We are all very excited and proud to be involved."

Kenneth Aldrich, Chairman of ISCO, issued a cautionary comment to its investors. "We are incredibly excited by the prospects of this new product from our Lifeline Skin Care subsidiary. Selling over 7,000 bottles through a very limited trial launch, as we have done, represents a significant first step, but it would be imprudent for us to base projections of future sales or profits on a sample base of this size."

ISCO investors should note that under ISCO's current revenue recognition policy, a large portion of the Q-4 2010 sales will not be included as revenue in the financial statements for the year ended December 31, 2010. Sales of these products meet our revenue recognition criteria after our 30 day product guarantee period has been completed.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product marketing plans, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

Exercise may reduce, and even reverse, bone loss caused by acidic hormone and radiation therapies used in the treatment of localized prostate cancer, thereby decreasing the potential risk of bone fractures and improving quality of life for these men, according to a study presented on October 28, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

"Prostate cancer patients are not routinely advised to exercise. Walking is one tool that prostate cancer patients can use to improve their health and minimize the side effects of cancer and cancer treatments," said Paula Chiplis, PhD., RN, the lead author of the study and a clinical instructor and senior research assistant at Johns Hopkins Hospital in Baltimore.

"Walking has no harmful side effects, if done moderately, but it can dramatically improve life for men suffering from side effects from some prostate cancer treatments."

Men with localized prostate cancer frequently receive radiation therapy followed by months of acidic hormone therapy to treat their cancerous acidic state. Read more...

Cardiofy Heart Care Supplement

BOSTON--A novel treatment for HIV could involve changing the genes in a person's immune cells and, ultimately, in his or her stem cells, as well. It might even lead to a cure for that deadly disease. Promising advances in that direction were presented here Monday at the 18th Conference on Retroviruses and Opportunistic Infections.

The pieces have been coming together for some time. First came the understanding that HIV enters a cell by grabbing on to a CD4 receptor molecule on the surface, and then on to a co-receptor molecule--the one most commonly used is called CCR5.

[More]

Original Article Source - Mass High Tech

Advanced Cell Technology Inc. has been given a patent for its nondestructive technique of obtaining human embryonic stem cell (hESC) lines. Called “single-blastomere” technology, the technique was referred to in a statement by ACT interim chairman and CEO Gary Rabin as “one of the most significant” among the Marlborough biotech’s more than 150 patents and patent applications.

“It will help us accelerate our progress on a number of fronts, including deriving embryonic stem cells which meet the regulatory standards of the European Medicines Agency and the US Food and Drug Administration, using the single-blastomere technology,” Rabin said, in the statement.

ACT (OTCBB: ACTC) said in a news release that its single-blastomere technique avoids embryo destruction by using a one-cell biopsy approach.

In January, the company pulled in a $25 million financing and was cleared by the FDA for its Investigational New Drug application to use hESCs in treating Dry Age-Related Macular Degeneration.

Rabin has been serving in his interim roles at ACT since mid-December, when William M. Caldwell IV, then chairman and CEO, died unexpectedly. Caldwell had held the CEO role of ACT since 2005 and the chairman post since 2006.

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its wholly owned subsidiary Lifeline Skin Care, Inc. ("LSC"), has now completed its evaluation of the highly successful trial launch of its new stem cell skin care product line in November and December 2010, and will move forward with its general marketing program.

Lifeline Skin Care products contain parthenogenetic stem cell extract and were developed by the ISCO research team in collaboration with world recognized cosmetic chemists. The breakthrough products deliver leading advances in skin rejuvenation technology that help to prevent and repair damaged skin. The products are available through our online store at http://www.lifelineskincare.com.

"Sales to date have greatly exceeded our expectations for the trial launch. These initial sales resulted from a very limited product offering made to subscribers of only one of the several newsletters of our marketing partner, John Mauldin, plus a small direct mailing to interested parties and ISCO's shareholders who had signed up for general corporate information through the ISCO website," said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.

Lifeline Skin Care is now ready to move forward to the next phase of distribution, which will commence near the end of March. That phase will consist initially of a customer solicitation conducted by John Mauldin's specialty Internet and direct response marketing organization. "We almost never endorse or sell a retail product," said Mr. Mauldin, "but the results of both our informal testing and the company's formal studies have convinced us that the Lifeline Skin Care products really are a game-changing advance in skin care. I have not seen such a strong response in online marketing in the last ten years. We are all very excited and proud to be involved."

Kenneth Aldrich, Chairman of ISCO, issued a cautionary comment to its investors. "We are incredibly excited by the prospects of this new product from our Lifeline Skin Care subsidiary. Selling over 7,000 bottles through a very limited trial launch, as we have done, represents a significant first step, but it would be imprudent for us to base projections of future sales or profits on a sample base of this size."

ISCO investors should note that under ISCO's current revenue recognition policy, a large portion of the Q-4 2010 sales will not be included as revenue in the financial statements for the year ended December 31, 2010. Sales of these products meet our revenue recognition criteria after our 30 day product guarantee period has been completed.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed cell based skin care products through its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product marketing plans, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

Joel Fuhrman, M.D.

Excess dietary salt is notorious for increasing blood pressure – blood volume increases, placing more stress on blood vessel walls. This forces the heart to pump harder against the pressure, and also structural changes that harden the vessel wall (this hardening is called stenosis) occur in response to these high pressures.
About one-third of all American adults and over 50% of those over the age of 55 have hypertension, and hypertension carries significant risks. Elevated blood pressure accounts for 62% of strokes and 49% of coronary heart disease. [1] Notably, the risk for heart attack and stroke begins climbing with systolic pressures (first number in the blood pressure reading) above 115 mm Hg – considered “normal” by most standards.[2] Also, dietary salt is not only dangerous to the cardiovascular system, but also contributes to kidney disease, osteoporosis , ulcers, and stomach cancer. [3] Read more...

Body cleansing, Body detoxify

Joel Fuhrman, M.D.

Excess dietary salt is notorious for increasing blood pressure – blood volume increases, placing more stress on blood vessel walls. This forces the heart to pump harder against the pressure, and also structural changes that harden the vessel wall (this hardening is called stenosis) occur in response to these high pressures.
About one-third of all American adults and over 50% of those over the age of 55 have hypertension, and hypertension carries significant risks. Elevated blood pressure accounts for 62% of strokes and 49% of coronary heart disease. [1] Notably, the risk for heart attack and stroke begins climbing with systolic pressures (first number in the blood pressure reading) above 115 mm Hg – considered “normal” by most standards.[2] Also, dietary salt is not only dangerous to the cardiovascular system, but also contributes to kidney disease, osteoporosis , ulcers, and stomach cancer. [3] Read more...

Body cleansing, Body detoxify

The human eye is a biological marvel. Charles Darwin considered it one of the biggest challenges to his theory of evolution, famously writing : that “To suppose that the eye with all its inimitable contrivances for adjusting the focus to different distances, for admitting different amounts of light, and for the correction of spherical and chromatic aberration, could have been formed by natural selection, seems, I freely confess, absurd in the highest degree.” Of course he did go on to explain how natural selection could account for the eye, but we can see why he wrote these words under the heading of “Organs of Extreme Perfection and Complication.” [More]

International Stem Cell Corporation Demonstrates Progress in the Use of Immune Matched Human Parthenogenetic Stem Cells to Promote the Development of Therapies for Diabetes and Liver Diseases

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, together with colleagues from ViaCyte (formerly Novocell), announced the successful derivation from its human parthenogenetic stem cells (hpSCs) of enriched cultures of definitive endoderm (DE). DE can be further developed into pancreas or liver cells. These new results create a platform for the development by ISCO of therapeutic products that have great potential to overcome the problem of rejection of transplanted cells by the patient's own immune system.

The results are described in a new article that will appear in Differentiation, the official journal of the International Society of Differentiation, published by Elsevier. The article concludes that, "Creation of the definitive endoderm lineages from hpSC represents the critical first step toward the development of hpSC-based cellular therapies for diseases of the liver or pancreas."

The article also describes improvement in an earlier published differentiation protocol. This new method extends ISCO's portfolio of intellectual property, demonstrating for the first time that the pre-treatment of undifferentiated cells by trichostatin A (TSA) significantly improves the efficacy of the differentiation procedure.

"This work represents a step forward in our ability to direct the differentiation of hpSCs to cell populations of sufficient purity for their eventual use to produce commercially viable populations of endoderm lineage cells such as liver and pancreas," said Nikolay Turovets, PhD, ISCO's Director of Research and Therapeutic Development, and the paper's co-author.

The published work was carried out in collaboration with scientists from ViaCyte, a leader in the direct differentiation of pluripotent stem cells toward definitive endoderm and pancreatic cells. The ViaCyte team was led by Dr. Baetge, currently Director of the Nestlé Institute of Health Sciences S.A., Lausanne, Switzerland, and Dr. D'Amour, ViaCyte's Director of Stem Cell Biology, both pioneers in the development of endoderm from human embryonic stem cells.

Andrey Semechkin, PhD, ISCO's CEO and the paper's co-author, said: "The fact that hpSC could be differentiated into progenitors of pancreatic and liver cells have now become a proven scientific fact. This data establishes hpSCs as a useful source of starting material in stem-cell based technologies and demonstrates excellent progress in therapeutic research."

According to earlier published scientific data, the most efficient method for deriving pancreatic and liver cells from human pluripotent stem cells is a method of direct differentiation that utilizes treatment of the stem cell cultures by specific signals directing differentiation toward particular lineages. Therefore it is extremely important that stem cells used for the differentiation process are able to respond to such signaling. Dr. Semechkin commented, "In this published paper we report for the first time that hpSCs can respond to well characterized differentiation signals. Moreover, we demonstrate that these unique cells respond to similar signaling factors and demonstrate gene expression dynamics and transitions that simulate properties of DE differentiation during vertebrate development and closely follow differentiation of human embryonic stem cells to DE. These data are extremely important as they demonstrate that hpSCs have therapeutic potential; however, parthenogenetic stem cells have an additional benefit of superior immune-matching capabilities and don't pose the same ethical questions associated with embryonic stem cells."

The Abstract of the paper is available on the Elsevier web site. The title of the paper is: "Human parthenogenetic stem cells produce enriched populations of definitive endoderm cells after trichostatin A pretreatment."

Full text article can be obtained upon request to corresponding author, Nikolay Turovets, PhD: nturovets@intlstemcell.com.

Additional information regarding ISCO's therapeutic projects is available on the ISCO website:http://www.internationalstemcell.com/therapeutics.htm.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and potential therapeutic applications, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Nikolay Turovets, PhD
nturovets@intlstemcell.com

The human eye is a biological marvel. Charles Darwin considered it one of the biggest challenges to his theory of evolution, famously writing : that “To suppose that the eye with all its inimitable contrivances for adjusting the focus to different distances, for admitting different amounts of light, and for the correction of spherical and chromatic aberration, could have been formed by natural selection, seems, I freely confess, absurd in the highest degree.” Of course he did go on to explain how natural selection could account for the eye, but we can see why he wrote these words under the heading of “Organs of Extreme Perfection and Complication.” [More]

International Stem Cell Corporation Demonstrates Progress in the Use of Immune Matched Human Parthenogenetic Stem Cells to Promote the Development of Therapies for Diabetes and Liver Diseases

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, together with colleagues from ViaCyte (formerly Novocell), announced the successful derivation from its human parthenogenetic stem cells (hpSCs) of enriched cultures of definitive endoderm (DE). DE can be further developed into pancreas or liver cells. These new results create a platform for the development by ISCO of therapeutic products that have great potential to overcome the problem of rejection of transplanted cells by the patient's own immune system.

The results are described in a new article that will appear in Differentiation, the official journal of the International Society of Differentiation, published by Elsevier. The article concludes that, "Creation of the definitive endoderm lineages from hpSC represents the critical first step toward the development of hpSC-based cellular therapies for diseases of the liver or pancreas."

The article also describes improvement in an earlier published differentiation protocol. This new method extends ISCO's portfolio of intellectual property, demonstrating for the first time that the pre-treatment of undifferentiated cells by trichostatin A (TSA) significantly improves the efficacy of the differentiation procedure.

"This work represents a step forward in our ability to direct the differentiation of hpSCs to cell populations of sufficient purity for their eventual use to produce commercially viable populations of endoderm lineage cells such as liver and pancreas," said Nikolay Turovets, PhD, ISCO's Director of Research and Therapeutic Development, and the paper's co-author.

The published work was carried out in collaboration with scientists from ViaCyte, a leader in the direct differentiation of pluripotent stem cells toward definitive endoderm and pancreatic cells. The ViaCyte team was led by Dr. Baetge, currently Director of the Nestlé Institute of Health Sciences S.A., Lausanne, Switzerland, and Dr. D'Amour, ViaCyte's Director of Stem Cell Biology, both pioneers in the development of endoderm from human embryonic stem cells.

Andrey Semechkin, PhD, ISCO's CEO and the paper's co-author, said: "The fact that hpSC could be differentiated into progenitors of pancreatic and liver cells have now become a proven scientific fact. This data establishes hpSCs as a useful source of starting material in stem-cell based technologies and demonstrates excellent progress in therapeutic research."

According to earlier published scientific data, the most efficient method for deriving pancreatic and liver cells from human pluripotent stem cells is a method of direct differentiation that utilizes treatment of the stem cell cultures by specific signals directing differentiation toward particular lineages. Therefore it is extremely important that stem cells used for the differentiation process are able to respond to such signaling. Dr. Semechkin commented, "In this published paper we report for the first time that hpSCs can respond to well characterized differentiation signals. Moreover, we demonstrate that these unique cells respond to similar signaling factors and demonstrate gene expression dynamics and transitions that simulate properties of DE differentiation during vertebrate development and closely follow differentiation of human embryonic stem cells to DE. These data are extremely important as they demonstrate that hpSCs have therapeutic potential; however, parthenogenetic stem cells have an additional benefit of superior immune-matching capabilities and don't pose the same ethical questions associated with embryonic stem cells."

The Abstract of the paper is available on the Elsevier web site. The title of the paper is: "Human parthenogenetic stem cells produce enriched populations of definitive endoderm cells after trichostatin A pretreatment."

Full text article can be obtained upon request to corresponding author, Nikolay Turovets, PhD: nturovets@intlstemcell.com.

Additional information regarding ISCO's therapeutic projects is available on the ISCO website:http://www.internationalstemcell.com/therapeutics.htm.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):

International Stem Cell Corporation is a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated technological developments and potential therapeutic applications, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Nikolay Turovets, PhD
nturovets@intlstemcell.com

A recently-released report by the Environmental Working Group (EWG) has found that the water supplies of many major cities are contaminated with hexavalent chromium, an industrial chemical toxin that does not get filtered out by most consumer water filtration devices. Thirty-one of the 35 water supplies tested contained hexavalent chromium, and 25 of them contained levels higher than a California-proposed maximum upper threshold for safety.

Topping the list of contaminated water supplies was Norman, Okla., with 12.9 parts per billion (ppb) of hexavalent chromium, followed by Honolulu, Hawaii, at 2.0 ppb and Riverside, Calif., at 1.69 ppb. Other highly-tainted cities include Madison, Wisc., San Jose, Calif., Tallahassee, Fla., and Albuquerque, N.M.

According to the National Toxicology Program, hexavalent chromium, also known as chromium-6, is linked to causing gastrointestinal tumors and other forms of cancer. International governing bodies have stated that it is toxic when inhaled. And the U.S. Environmental Protection Agency (EPA) has declared hexavalant chromium "likely to be carcinogenic to humans." Read more...

Cardiofy Heart Care Supplement

GENEVIEVE CARBERY
Tue, Nov 02, 2010

A new study found alcohol was the most dangerous of 20 legal and illegal drugs when the two criteria of harm to the user and harm to others were combined ALCOHOL IS more dangerous than crack cocaine and heroin when damage to users themselves and to wider society are combined, a study has found. The research, published yesterday in theLanc et medical journal, rated alcohol almost three times as harmful as cocaine or tobacco and some eight times as harmful as ecstasy. Alcohol was found to be the most harmful of 20 legal and illegal drugs examined when the two criteria of harm to the user and harm to others were combined. The study was conducted by a group of scientists including Britain’s Independent Scientific Committee on Drugs and an expert adviser to the European Monitoring Centre for Drugs and Drug Addiction. Read more...

Cardiofy Heart Care Supplement